The specialist cancer drug discovery and development business has updated on trading for the year ended 30 June 2017. Sareum now expects that subject to audit, net profit and cash balances will be ahead of market expectations. Our forecasts were suggesting net profit of £0.2m and cash of £2.1m and we therefore expect those to be exceeded. We have increased our expected cash balances by 10% to £2.3m and continue to forecast a flat working capital position implying that the en
23 Aug 2017
Cash and profits to be ahead of expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cash and profits to be ahead of expectations
Sareum Holdings plc (SAR:LON) | 33.5 3.4 44.1% | Mkt Cap: 34.0m
- Published:
23 Aug 2017 -
Author:
Derren Nathan -
Pages:
6
The specialist cancer drug discovery and development business has updated on trading for the year ended 30 June 2017. Sareum now expects that subject to audit, net profit and cash balances will be ahead of market expectations. Our forecasts were suggesting net profit of £0.2m and cash of £2.1m and we therefore expect those to be exceeded. We have increased our expected cash balances by 10% to £2.3m and continue to forecast a flat working capital position implying that the en